Review of microRNA in osteosarcoma and chondrosarcoma

Medical Oncology

Volumn 32, Issue 6, 2015, Pages

  Chang, Le ^a   Shrestha, Swati ^a   LaChaud, Greg ^a   Scott, Michelle A ^b   James, Aaron W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Chondrosarcoma; microRNA; miRNA; Oncogene; Osteosarcoma; Skeletal sarcoma; Tumor suppressor

Indexed keywords

ANTINEOPLASTIC AGENT; MICRORNA; PROTEIN P53; TRANSCRIPTOME;

APOPTOSIS; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL SURVIVAL; CHONDROSARCOMA; GENE EXPRESSION; HUMAN; OSTEOSARCOMA; PATIENT RISK; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; BONE TUMOR; GENETICS;

ANIMALS; BONE NEOPLASMS; CHONDROSARCOMA; HUMANS; MICRORNAS; OSTEOSARCOMA; TRANSCRIPTOME;

EID: 84928653204     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0613-z     Document Type: Review

References (93)

1. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38(6):724–33.
2. Yates LA, Norbury CJ, Gilbert RJ. The long and short of microRNA. Cell. 2013;153(3):516–9.
3. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch. 2008;452(1):1–10.
4. Mishra PJ, Merlino G. MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest. 2009;119(8):2119–23.
5. Mishra PJ. The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins. Pharmacogenomics. 2012;13(12):1321–4.
6. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
7. Rytting M, et al. Osteosarcoma in preadolescent patients. Clin Orthop Relat Res. 2000;373:39–50.
8. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest. 2001;19(3):292–315.
9. Levine AJ, Hu W, Feng Z. The P53 pathway: what questions remain to be explored? Cell Death Differ. 2006;13(6):1027–36.
10. Lau CC, et al. Frequent amplification and rearrangement of chromosomal bands 6p12-p21 and 17p11.2 in osteosarcoma. Genes Chromosomes Cancer. 2004;39(1):11–21.
11. Ognjanovic S, et al. Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer. 2012;118(5):1387–96.
12. Tsuchiya T, et al. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 2000;120(2):91–8.
13. Jacks T, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4(1):1–7.
14. He L, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130–4.
15. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193–9.
16. Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol. 2012;26(2):79–86.
17. He C, et al. Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun. 2009;388(1):35–40.
18. Zhou Y, et al. miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 2014;33:12.
19. Lee KW, et al. Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma. Cancer Lett. 2014;343(1):62–73.
20. Wu J, et al. TWIST interacts with β-catenin signaling on osteosarcoma cell survival against cisplatin. Mol Carcinog. 2014;53(6):440–6.
21. Zhou Y, et al. TWIST interacts with endothelin-1/endothelin A receptor signaling in osteosarcoma cell survival against cisplatin. Oncol Lett. 2013;5(3):857–61.
22. Maire G, et al. Analysis of miRNA-gene expression-genomic profiles reveals complex mechanisms of microRNA deregulation in osteosarcoma. Cancer Genet. 2011;204(3):138–46.
23. Wang S, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261–71.
24. Zhang K, et al. A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF. Int J Clin Exp Pathol. 2014;7(9):5701–8.
25. Zhao D, et al. VEGF-mediated suppression of cell proliferation and invasion by miR-410 in osteosarcoma. Mol Cell Biochem. 2015;400(1–2):87–95.
26. Kwiecinski M, et al. Expression of platelet-derived growth factor-C and insulin-like growth factor I in hepatic stellate cells is inhibited by miR-29. Lab Invest. 2012;92(7):978–87.
27. Czabotar PE, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.
28. Trieb K, Sulzbacher I, Kubista B. Bcl-2 correlates with localization but not outcome in human osteosarcoma. Oncol Lett. 2013;6(2):559–61.
29. Nedelcu T, et al. Livin and Bcl-2 expression in high-grade osteosarcoma. J Cancer Res Clin Oncol. 2008;134(2):237–44.
30. Aqeilan RI, Calin GA, Croce CM. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010;17(2):215–20.
31. Xia L, et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer. 2008;123(2):372–9.
32. Zhang H, et al. microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010;24(5):1363–9.
33. Fletcher C, Unni KK, Mertens F. World Health Organization classification of tumors. Lyon: IARC Press; 2002.
34. Rozeman LB, Cleton-Jansen AM, Hogendoorn PC. Pathology of primary malignant bone and cartilage tumours. Int Orthop. 2006;30(6):437–44.
35. Zhu Z, et al. MicroRNA-100 resensitizes resistant chondrosarcoma cells to cisplatin through direct targeting of mTOR. Asian Pac J Cancer Prev. 2014;15(2):917–23.
36. Huang J, et al. MicroRNA-100 inhibits osteosarcoma cell proliferation by targeting Cyr61. Tumour Biol. 2014;35(2):1095–100.
37. Lauvrak SU, et al. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes. Br J Cancer. 2013;109(8):2228–36.
38. Yoshitaka T, et al. Analysis of microRNAs expressions in chondrosarcoma. J Orthop Res. 2013;31(12):1992–8.
39. Petrelli A, et al. By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy. Oncotarget. 2015;6(4):2315–30.
40. Li Z, et al. MicroRNA-100 regulates pancreatic cancer cells growth and sensitivity to chemotherapy through targeting FGFR3. Tumour Biol. 2014;35(12):11751–9.
41. Zhou S, et al. Prognostic value of microRNA-100 in esophageal squamous cell carcinoma. J Surg Res. 2014;192(2):515–20.
42. Sarver AL, et al. MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet J Rare Dis. 2013;8:7.
43. Wang L, et al. microRNA-377 suppresses the proliferation of human osteosarcoma MG-63 cells by targeting CDK6. Tumour Biol. 2015. doi:10.1007/s13277-014-3034-2.
44. Namløs HM, et al. Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS ONE. 2012;7(10):e48086.
45. Mak IW, et al. The epigenetic regulation of SOX9 by miR-145 in human chondrosarcoma. J Cell Biochem. 2015;116(1):37–44.
46. Lei P, et al. microRNA-145 inhibits osteosarcoma cell proliferation and invasion by targeting ROCK1. Mol Med Rep. 2014;10(1):155–60.
47. Li E, et al. MiR-145 inhibits osteosarcoma cells proliferation and invasion by targeting ROCK1. Tumour Biol. 2014;35(8):7645–50.
48. Lochhead PA, et al. Activating ROCK1 somatic mutations in human cancer. Oncogene. 2010;29(17):2591–8.
49. Selbach M, et al. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58–63.
50. Zhao G, et al. MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS ONE. 2013;8(1):e53906.
51. Chun-Zhi Z, et al. MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 2010;10:367.
52. Galardi S, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282(32):23716–24.
53. Lim LP, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769–73.
54. Tang F, et al. MicroRNA expression profiling of single whole embryonic stem cells. Nucleic Acids Res. 2006;34(2):e9.
55. Song B, et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009;28(46):4065–74.
56. Yuan J, et al. The expression and function of miRNA-451 in osteosarcoma. Med Oncol. 2015;32(1):324.
57. Chong Y, et al. MicroRNA-503 acts as a tumor suppressor in osteosarcoma by targeting L1CAM. PLoS ONE. 2014;9(12):e114585.
58. Cai H, et al. Serum miR-195 is a diagnostic and prognostic marker for osteosarcoma. J Surg Res. 2014;194(2):505–10.
59. Dylla L, Moore C, Jedlicka P. MicroRNAs in Ewing sarcoma. Front Oncol. 2013;3:65.
60. Karnuth B, et al. Differentially expressed miRNAs in Ewing sarcoma compared to mesenchymal stem cells: low miR-31 expression with effects on proliferation and invasion. PLoS ONE. 2014;9(3):e93067.
61. Hu H, et al. Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett. 2012;4(5):1037–42.
62. Gao Y, et al. miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression. Biochem Biophys Res Commun. 2014;444(2):230–4.
63. Li X, et al. MicroRNA-19b targets Mfn1 to inhibit Mfn1-induced apoptosis in osteosarcoma cells. Neoplasma. 2014;61(3):265–73.
64. Wang XH, et al. microRNA-25 promotes osteosarcoma cell proliferation by targeting the cell-cycle inhibitor p27. Mol Med Rep. 2014;10(2):855–9.
65. Montanini L, et al. MicroRNA cloning and sequencing in osteosarcoma cell lines: differential role of miR-93. Cell Oncol (Dordr). 2012;35(1):29–41.
66. Pei H, et al. MiR-135b promotes proliferation and invasion of osteosarcoma cells via targeting FOXO1. Mol Cell Biochem. 2015;400(1–2):245–52.
67. Lulla RR, et al. Identification of differentially expressed MicroRNAs in osteosarcoma. Sarcoma. 2011;2011:732690.
68. Won KY, et al. MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma. Hum Pathol. 2013;44(8):1648–55.
69. Cai H, et al. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. Med Oncol. 2013;30(2):499.
70. Wang X, et al. MicroRNA-214 regulates osteosarcoma survival and growth by directly targeting phosphatase and tensin homolog. Mol Med Rep. 2014;10(6):3073–9.
71. Xu Z, Wang T. miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1. Biochem Biophys Res Commun. 2014;449(2):190–5.
72. Li H, et al. miR-542-3p overexpression is associated with enhanced osteosarcoma cell proliferation and migration ability by targeting Van Gogh-like 2. Mol Med Rep. 2015;11(2):851–6.
73. Guo S, et al. miR-22 inhibits osteosarcoma cell proliferation and migration by targeting HMGB1 and inhibiting HMGB1-mediated autophagy. Tumour Biol. 2014;35(7):7025–34.
74. Wang G, et al. miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1. Tumour Biol. 2015. doi:10.1007/s13277-015-3120-0.
75. Zhang W, et al. The microRNA-29 plays a central role in osteosarcoma pathogenesis and progression. Mol Biol (Mosk). 2012;46(4):622–7.
76. Di Fiore R, et al. MicroRNA-29b-1 impairs in vitro cell proliferation, self-renewal and chemoresistance of human osteosarcoma 3AB-OS cancer stem cells. Int J Oncol. 2014;45(5):2013–23.
77. Xu JQ, et al. MicroRNA-32 inhibits osteosarcoma cell proliferation and invasion by targeting Sox9. Tumour Biol. 2014;35(10):9847–53.
78. Xu N, et al. MicroRNA-33b suppresses migration and invasion by targeting c-Myc in osteosarcoma cells. PLoS ONE. 2014;9(12):e115300.
79. Lv H, et al. A polymorphism site in the pre-miR-34a coding region reduces miR-34a expression and promotes osteosarcoma cell proliferation and migration. Mol Med Rep. 2014;10(6):2912–6.
80. Tian Y, Zhang YZ, Chen W. MicroRNA-199a-3p and microRNA-34a regulate apoptosis in human osteosarcoma cells. Biosci Rep. 2014;34(4):479.
81. Liu Z, et al. The tumor-suppressive microRNA-135b targets c-myc in osteosarcoma. PLoS ONE. 2014;9(7):e102621.
82. Osaki M, et al. MicroRNA-143 regulates human osteosarcoma metastasis by regulating matrix metalloprotease-13 expression. Mol Ther. 2011;19(6):1123–30.
83. Zhao M, et al. The downregulation of miR-144 is associated with the growth and invasion of osteosarcoma cells through the regulation of TAGLN expression. Int J Mol Med. 2014;34(6):1565–72.
84. Duan Z, et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 2011;10(8):1337–45.
85. Sun Z, et al. miR-202 suppresses proliferation and induces apoptosis of osteosarcoma cells by downregulating Gli2. Mol Cell Biochem. 2014;397(1–2):277–83.
86. Luo XJ, et al. MicroRNA-212 inhibits osteosarcoma cells proliferation and invasion by down-regulation of Sox4. Cell Physiol Biochem. 2014;34(6):2180–8.
87. Shen L, et al. MicroRNA-217 regulates WASF3 expression and suppresses tumor growth and metastasis in osteosarcoma. PLoS ONE. 2014;9(10):e109138.
88. Zhang H, et al. Prognostic value of microRNA-223/epithelial cell transforming sequence 2 signaling in patients with osteosarcoma. Hum Pathol. 2014;45(7):1430–6.
89. Xu M, et al. miR-382 inhibits tumor growth and enhance chemosensitivity in osteosarcoma. Oncotarget. 2014;5(19):9472–83.
90. Sun XH, et al. miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2). Tumour Biol. 2014;36(3):2127–34.
91. Xu H, Liu X, Zhao J. Down-regulation of miR-3928 promoted osteosarcoma growth. Cell Physiol Biochem. 2014;33(5):1547–56.
92. Poos K, et al. How microRNA and transcription factor co-regulatory networks affect osteosarcoma cell proliferation. PLoS Comput Biol. 2013;9(8):e1003210.
93. Wang Y, Zhao W, Fu Q. miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem. 2013;384(1–2):105–11.